Live Chat

Why GSK’s Disclosures May Have Been Insufficient

Glaxo Smith Klein (GSK), the major pharmaceutical manufacturer, has produced the antidepressant Paxil (paroxetine) for years. And for the last half decade, GSK has continued to supply the market – and, indirectly, pregnant women – with this dangerous antidepressant, despite the Food and Drug Administration’s (FDA) warning that medical studies have demonstrate that Paxil substantially increases the probability that the children of pregnant consumers may be born with birth defects such as PPHN.


Tragically, the highest risk period for Paxil is the first twenty weeks of pregnancy: a period during which most pregnant women do not realize they are pregnant. According to multiple medical studies, the consumption of Paxil during the first trimester elevated the risk of heart defects by between 150 and 200 percent. The question many experts are raising as a result is, “Were GSK’s disclosures sufficient to appropriately warn women who were unknowningly pregnant?” A number of victims feel that the answer is, “No.”


Attorneys at Fears Nachawati specialize in protecting the rights of victims like pregnant Paxil patients and their injured children. If you’ve suffered as a result of your SSRI prescription, you should give us a call. Put our experience and expertise to work for you! For a free consultation, call us at 1.866.545.8364 or email

Drug Litigation

Why GSK’s Disclosures May Have Been Insufficient